Metformin, a widely used Type 2 diabetes medication, is being investigated as a potential disease-modifying treatment for Parkinson's disease. This clinical trial (NCT07229651) evaluates whether metformin can slow Parkinson's disease progression through AMPK activation and downstream neuroprotective mechanisms. The trial represents a significant step in drug repurposing for neurodegenerative diseases, leveraging metformin's well-established safety profile and known CNS penetration.
Metformin's potential in PD stems from its ability to activate AMPK, a central cellular energy sensor that coordinates metabolic homeostasis and activates downstream pathways critical for neuronal survival. By targeting fundamental cellular processes involved in neurodegeneration, metformin may offer disease-modifying benefits rather than merely symptomatic relief.
| Parameter |
Value |
| NCT Number |
NCT07229651 |
| Phase |
Phase 2/3 |
| Status |
Recruiting |
| Sponsor |
Multiple academic centers |
| Intervention |
Metformin hydrochloride |
| Dose |
500-1000 mg daily (titrated) |
| Duration |
52 weeks treatment |
| Sample Size |
Approximately 200 participants |
| Primary Endpoint |
Change in MDS-UPDRS Part 3 score |
| Key Secondary |
Change in DAT-SPECT imaging |
¶ Background and Rationale
Metformin activates AMP-activated protein kinase (AMPK), a central cellular energy sensor that coordinates metabolic homeostasis. AMPK serves as a master regulator of cellular energy metabolism, activating catabolic processes while inhibiting anabolic ones when energy levels are low. This activation triggers a cascade of protective cellular responses particularly relevant to neurodegeneration.
The molecular mechanism of metformin involves several key steps:
- Mitochondrial Complex I Inhibition: Metformin inhibits mitochondrial complex I, increasing the AMP:ATP ratio, which directly activates AMPK
- mTOR Inhibition: AMPK activation inhibits mTORC1, promoting autophagy and lysosomal degradation of misfolded proteins
- Metabolic Effects: Improves insulin sensitivity, reduces hepatic gluconeogenesis, and reduces oxidative stress
- Neuroprotection: Direct neuroprotective effects through AMPK signaling in neurons, including enhanced mitochondrial biogenesis
- Anti-inflammatory Effects: Reduces microglial activation and neuroinflammation through AMPK-dependent pathways
Strong preclinical evidence supports metformin in PD:
MPTP Models
- Metformin protects dopaminergic neurons in MPTP-treated mice
- Reduces loss of tyrosine hydroxylase-positive neurons in the substantia nigra
- Improves motor performance in MPTP-challenged animals
α-Synuclein Models
- Reduces aggregation through autophagy enhancement
- Decreases phosphorylated α-synuclein burden
- Improves behavioral deficits in α-synuclein transgenic models
Inflammatory Models
- Reduces microglial activation and pro-inflammatory cytokine production
- Attenuates neuroinflammation-induced dopaminergic neuron loss
- Modulates peripheral immune responses
Metabolic Models
- Improves mitochondrial function and ATP production
- Enhances mitochondrial biogenesis through PGC-1α activation
- Reduces oxidative stress markers
Metformin offers several advantages as a repurposed drug:
- Safety profile: Well-established safety in millions of patients over decades
- BBB penetration: Demonstrated CNS penetration in human studies
- Cost: Generic availability makes it accessible
- Accessibility: Oral administration simplifies delivery
- Dosing: Well-characterized dose-response relationship
- Pharmacokinetics: Well-understood absorption, distribution, metabolism, and excretion
Inclusion Criteria
- Age 40-80 years
- Parkinson's disease diagnosis (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Disease duration 1-10 years
- Stable PD medication for ≥4 weeks
- Montreal Cognitive Assessment (MoCA) score ≥24
Exclusion Criteria
- Diabetes mellitus (excluded to isolate PD effect)
- Significant cognitive impairment (MMSE <24)
- Previous metformin use (within 12 months)
- Renal impairment (eGFR <60 mL/min/1.73m²)
- Hepatic impairment
- Cardiovascular events within 6 months
- Current participation in other clinical trials
¶ Randomization and Blinding
This trial employs a randomized, double-blind, placebo-controlled design:
- Participants randomized 1:1 to metformin or placebo
- Matching tablets ensure blinding
- Independent statistician oversees randomization
- Interim analysis planned at 50% enrollment
Primary
- Change in MDS-UPDRS Part 3 (motor) score at 52 weeks
- Change in DAT-SPECT imaging (secondary primary)
Secondary
- Motor complications development (dyskinesias, motor fluctuations)
- Non-motor symptoms (cognitive, autonomic, sleep)
- Quality of life (PDQ-39)
- CSF biomarkers (α-synuclein, tau, NfL)
- Hospitalization rates
- Adverse event frequency and severity
| Visit |
Timing |
Assessments |
| Screening |
Week -4 to 0 |
Medical history, physical, cognitive assessment |
| Baseline |
Week 0 |
MDS-UPDRS, DAT-SPECT, CSF collection, randomization |
| Week 13 |
Week 13 |
MDS-UPDRS, safety labs, adverse events |
| Week 26 |
Week 26 |
MDS-UPDRS, PDQ-39, secondary endpoints |
| Week 39 |
Week 39 |
MDS-UPDRS, safety assessment |
| Week 52 |
Week 52 |
All primary and secondary endpoints, DAT-SPECT |
Metformin treatment may be monitored through multiple biomarker categories:
Metabolic Biomarkers
- Fasting glucose and insulin levels
- HbA1c (glycated hemoglobin)
- Body mass index and weight changes
- Lipid panel (cholesterol, triglycerides)
Neurodegeneration Biomarkers
- Plasma and CSF Neurofilament light chain (NfL)
- CSF α-synuclein RT-QuIC
- Total tau and phosphorylated tau
- Amyloid-β 1-42
Imaging Biomarkers
- DAT-SPECT for dopaminergic integrity
- MRI for brain volume changes
- PET imaging for amyloid/tau (subset)
flowchart TD
A["Metformin"] --> B["Mitochondrial Complex I Inhibition"]
B --> C["Increased AMP:ATP Ratio"]
C --> D["AMPK Activation"]
D --> E1["mTORC1 Inhibition"]
D --> E2["PGC-1α Activation"]
D --> E3["Autophagy Enhancement"]
E1 --> F1["Autophagic Clearance of α-Synuclein"]
E2 --> F2["Mitochondrial Biogenesis"]
E3 --> F1
E2 --> F3["Reduced Oxidative Stress"]
F1 --> G["Reduced α-Synuclein Aggregation"]
F2 --> G
F3 --> H["Neuronal Survival"]
G --> H
H --> I["Slowed PD Progression"]
style I fill:#c8e6c9,stroke:#333
Potential Benefits
- Disease modification through AMPK activation
- Improved glucose metabolism in brain
- Reduced neuroinflammation
- Enhanced autophagy of misfolded proteins
- Potential for combined motor and non-motor symptom benefits
- May reduce need for escalating dopaminergic medications
Challenges
- May require high doses for optimal CNS effect
- Gastrointestinal side effects possible (nausea, diarrhea)
- Long-term safety in non-diabetic PD population not fully characterized
- Potential for vitamin B12 deficiency with long-term use
- Drug interactions with common PD medications
¶ Competitive Landscape
Metformin enters a competitive field of repurposed drugs for PD:
| Agent |
Mechanism |
Stage |
Notes |
| Metformin |
AMPK activator |
Phase 2/3 |
Repurposed generic, oral |
| Exenatide |
GLP-1 agonist |
Phase 3 |
Subcutaneous injection |
| GLP-1 analogs (linclatide) |
GLP-1 agonist |
Phase 2/3 |
Multiple candidates |
| Ambroxol |
Glucocerebrosidase chaperone |
Phase 2 |
Targets GBA mutations |
| Inosine |
Urate elevation |
Phase 3 |
Antioxidant approach |
| Azilect |
MAO-B inhibition |
Approved |
Disease-modifying claims |
The trial builds on extensive preclinical data and some human correlative studies:
Clinical Observations in Diabetes
- Reduced PD incidence in metformin-treated diabetic patients (epidemiological studies)
- Improved cognitive outcomes in diabetic patients on metformin
- Established CNS penetration in humans
Mechanistic Studies
- AMPK activation in post-mortem PD brain tissue
- Autophagy impairment in PD models and patient tissue
- Mitochondrial dysfunction as central to PD pathogenesis
Several trials are investigating metabolic interventions in PD:
- GLP-1 receptor agonists (exenatide, liraglutide)
- Inosine for urate elevation
- Dietary interventions (fasting, calorie restriction)
- Ketogenic diet trials
- Mitochondrial-targeted antioxidants
If successful, metformin could become a cornerstone of disease-modifying therapy in PD:
- Combination approaches with other neuroprotective agents
- Biomarker-driven patient selection
- Prevention trials in at-risk populations
- Pediatric formulations for earlier intervention